Company Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates.
The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.
It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Country | France |
| Founded | 1999 |
| IPO Date | Feb 7, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 216 |
| CEO | Dr. Andre Choulika Ph.D. |
Contact Details
Address: 8 Rue De La Croix Jarry Paris, Lle-de-france, I0 75013 France | |
| Phone | 33181691600 |
| Website | cellectis.com |
Stock Details
| Ticker Symbol | CLLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001627281 |
| CUSIP Number | 15117K103 |
| ISIN Number | US15117K1034 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David j. d. Sourdive Ph.D. | Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director |
| Dr. Andre Choulika Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer |
| Valerie Cros | Principal Financial Officer and Principal Accounting Officer |
| Jean Charles Epinat | Chief Technological Officer |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Stephan Reynier M.Sc. | Chief Regulatory and Pharmaceutical Compliance Officer |
| Marie-Bleuenn Terrier | General Counsel and Secretary of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Kyung Nam-Wortman | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| Jun 12, 2024 | 6-K | Report of foreign issuer |
| Jun 4, 2024 | 6-K | Report of foreign issuer |
| May 29, 2024 | 6-K | Report of foreign issuer |
| May 28, 2024 | 6-K | Report of foreign issuer |
| May 28, 2024 | 6-K | Report of foreign issuer |
| May 28, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 6-K | Report of foreign issuer |